Zenas BioPharma (NASDAQ:ZBIO) CEO Leon Moulder, Jr. Purchases 35,000 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. bought 35,000 shares of Zenas BioPharma stock in a transaction on Wednesday, April 29th. The shares were purchased at an average cost of $17.62 per share, with a total value of $616,700.00. Following the acquisition, the chief executive officer directly owned 1,786,039 shares of the company’s stock, valued at approximately $31,470,007.18. The trade was a 2.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Zenas BioPharma Stock Performance

Shares of NASDAQ:ZBIO opened at $17.55 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.61 and a quick ratio of 5.61. The business’s 50 day moving average price is $22.48 and its 200-day moving average price is $27.14. The firm has a market capitalization of $1.01 billion, a PE ratio of -2.25 and a beta of -0.54. Zenas BioPharma, Inc. has a 1 year low of $8.51 and a 1 year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Monday, April 13th. The company reported ($1.10) EPS for the quarter. As a group, equities research analysts expect that Zenas BioPharma, Inc. will post -4.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZBIO. SR One Capital Management LP grew its holdings in shares of Zenas BioPharma by 2.6% in the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after purchasing an additional 126,315 shares during the period. NEA Management Company LLC raised its stake in Zenas BioPharma by 28.9% during the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after purchasing an additional 789,500 shares during the period. Federated Hermes Inc. boosted its holdings in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after purchasing an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc purchased a new stake in shares of Zenas BioPharma in the 4th quarter valued at approximately $38,402,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ZBIO shares. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a report on Tuesday, March 17th. Citigroup decreased their target price on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Finally, Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Saturday, March 21st. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $44.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.